Medpace Holdings, Inc.
Medpace Holdings, Inc. Q2 FY26 Results — Earnings Call Analysis
Q2 FY26 earnings call: what management said on revenue, margins and capex.
What the Q2 FY26 call signalled
0 of 3 strong
The short version
- Revenue is expected to remain within the current guidance range for 2026 despite higher cancellations and a sub-1 book-to-bill ratio. - Medpace reconfirmed 2026 guidance for revenue, EBITDA, net income, and EPS, indicating confidence in hitting targets despite higher cancellations.
From Medpace Holdings, Inc.'s Q2 FY26 earnings-call transcript · updated 30 May 2026.
Revenue & Sales Performance
- Revenue is expected to remain within the current guidance range for 2026 despite higher cancellations and a sub-1 book-to-bill ratio.
- Backlog coverage beyond 1 year has declined for six consecutive quarters, raising concerns about near-term sequential revenue growth.
- Growth depends on either a reduction in cancellations or an increase in new awards and pipeline expansion.
- There is a lag of 2 to 3 quarters between booking awards and booking recognition, impacting revenue cadence.
2 more points from Medpace Holdings, Inc.'s call on revenue
Create a free account to keep reading this call
Profitability & Margins
See what Medpace Holdings, Inc. said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- Medpace plans to continue investing in AI and technology, but expects no net productivity benefit from AI in the near term (next 1-2 years) due to required investments offsetting gains.
- AI initiatives are seen as a multi-year effort aiming for future efficiency improvements.
- The company is focused on expanding its pipeline and improving win rates through unspecified initiatives.
- Medpace continues to hire, reflecting confidence in future growth despite cancellations.
Fundraising & Capital Structure
See what Medpace Holdings, Inc. said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
- The company distinguishes between backlog (ongoing projects with recognized bookings) and pre-backlog (authorized but not yet started projects which may never start).
- Pre-backlog size is generally comparable to or somewhat larger than the backlog.
- Bookings to backlog conversion takes on average about 3 to 5 quarters.
- Bookings recognition generally coincides with "first patient in" for clinical trials.
- The current quarter showed good awards (wins) and win rates, but many projects are in pre-backlog and have not yet started.
2 more points from Medpace Holdings, Inc.'s call on order book
Create a free account to keep reading this call
Continue your research
Others in Life Sciences Tools and Services this season
- Revvity, Inc. (Q2 FY26)
Revvity, Inc. Q2 FY26 quarterly results analysis. 2026 revenue guidance updated to $2.81 billion - $2.84 billion, with pro forma organic growth expected at 3% t
- Illumina, Inc. (Q2 FY26)
Illumina, Inc. Q2 FY26 quarterly results analysis. Illumina expects continued strong momentum in clinical sales, projecting mid-teens growth for the clinical ma
- Mettler-Toledo International Inc. (Q2 FY26)
Mettler-Toledo International Inc. Q2 FY26 quarterly results analysis. The company expects local currency sales growth of approximately 4% for full year 2026, in
- West Pharmaceutical Services, Inc. (Q2 FY26)
West Pharmaceutical Services, Inc. Q2 FY26 quarterly results analysis. Revenue growth guidance for 2026 increased to 7% to 9% organic growth, reflecting strong
Potential multibaggers · Q2 FY27
This quarter's potential multibaggers
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Arthneeti Pro · Annual
Medpace Holdings, Inc. and 15K+ more earnings calls,
for less than your morning chai
a day
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Medpace Holdings, Inc. Q2 FY26 results?
- Revenue is expected to remain within the current guidance range for 2026 despite higher cancellations and a sub-1 book-to-bill ratio. - Medpace reconfirmed 2026 guidance for revenue, EBITDA, net income, and EPS, indicating confidence in hitting targets despite higher cancellations.
What is Medpace Holdings, Inc. share price analysis?
Medpace Holdings, Inc. currently shows a below-average growth signal. The stock trades at a P/E of 27.0 with a market cap of $12,798. Investors should review the full earnings analysis for detailed insights.
Is Medpace Holdings, Inc. planning capital expenditure?
- Medpace plans to continue investing in AI and technology, but expects no net productivity benefit from AI in the near term (next 1-2 years) due to required investments offsetting gains.
Keep Medpace Holdings, Inc. on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.